|
Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma. |
| |
|
|
|
Stock and Other Ownership Interests - TeneoBio |
Travel, Accommodations, Expenses - TeneoBio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
|
Stock and Other Ownership Interests - Teneobio |
Research Funding - Amunix (I) |
Patents, Royalties, Other Intellectual Property - Spouse is CEO of Biotech company Amunix and holds multiple technology patents for the treatment of various diseases. (I) |
| |
|
Stock and Other Ownership Interests - Indapta Therapeutics |
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Indapta Therapeutics; Sanofi; Takeda; TeneoBio |
Research Funding - Bluebird Bio; Celgene; Janssen |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
Research Funding - Quadriga Biosciences; Sutter Medical Group; TeneoBio |
| |
|
|
|
Stock and Other Ownership Interests - TeneoBio |